ResMed (RMD) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $252.86 -0.08%
EPS Growth %: +5.1%
Financial Fact:
Diluted weighted average shares outstanding: 142.09M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +5.1%
Financial Fact:
Diluted weighted average shares outstanding: 142.09M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $0.65, in-line with the analyst estimate of $0.65. Revenue for the quarter came in at $422.5 million versus the consensus estimate of $425.76 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Preferred Bank (PFBC) Tops Q3 EPS by 4c
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
